Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway.
Location: United States, New Jersey, South Brunswick
Employees: 11-50
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | Avoro Capi... | avorocapit... |
Mentions in press and media 13
| Date | Title | Description |
| 24.07.2024 | Armistice Capital, Other Investors Show an Interest in Ocular Research | Created by Carl Williams Jul 24 2024, 02:34 AM EDT Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 12.03.2024 | Outlook Therapeutics® Announces Effective Date for 1-for-20 Reverse Stock Split | - |
| 30.08.2022 | Food allergy biotech gets $50M loan; Sean Ianchulev’s medical device company raises a $23M Series B | Alladapt Immunotherapeutics put out word on Tuesday that it has entered into a term loan agreement with Hercules Capital for up to $50 million. According to the biotech, which focuses on IgE-mediated food allergies, th... |
| 12.01.2022 | Corporate Presentation: January 2022 | Corporate Presentation January 2022 NASDAQ: OTLK outlooktherapeutics.com Enhancing the standard of care for retinal disorders by working to achieve the first FDA approval for bevacizumab in ophthalmology 2 Disclaimer This presentation conta... |
| 07.12.2021 | Corporate Presentation: December 2021 | Corporate Presentation December 2021 NASDAQ: OTLK outlooktherapeutics.com Enhancing the standard of care for retinal disorders by working to achieve the first FDA approval for bevacizumab in ophthalmology 2 Disclaimer This presentation cont... |
| 16.11.2021 | Corporate Presentation: November 2021 | Corporate Presentation November 2021 NASDAQ: OTLK outlooktherapeutics.com Enhancing the standard of care for retinal disorders by working to achieve the first FDA approval for bevacizumab in ophthalmology 2 Disclaimer This presentation cont... |
| 03.09.2021 | Corporate Presentation: September 2021 | Corporate Presentation September 2021 NASDAQ: OTLK outlooktherapeutics.com Disclaimer This presentation contains forward-looking statements about Outlook Therapeutics, Inc. ("Outlook Therapeutics" or the "Company") based... |
| 10.08.2021 | Corporate Presentation: August 2021 | CORPORATE PRESENTATION August 2021 NASDAQ: OTLK outlooktherapeutics.com Disclaimer This presentation contains forward-looking statements about Outlook Therapeutics, Inc. ("Outlook Therapeutics" or the "Company") based on... |
| 08.07.2021 | Corporate Presentation: July 2021 | CORPORATE PRESENTATION July 2021 NASDAQ: OTLK outlooktherapeutics.com Disclaimer This presentation contains forward-looking statements about Outlook Therapeutics, Inc. ("Outlook Therapeutics" or the "Company") based on m... |
| 07.06.2021 | OUTLOOK THERAPEUTICS, INC. Corporate Presentation: June 2021 | CORPORATE PRESENTATION June 2021 NASDAQ: OTLK outlooktherapeutics.com Disclaimer This presentation contains forward-looking statements about Outlook Therapeutics, Inc. ("Outlook Therapeutics" or the "Company") based on m... |
Show more